Phase I study of single-agent CC-292, a highly selective Bruton's tyrosine kinase inhibitor, in relapsed/refractory chronic lymphocytic leukemia

被引：59

作者：

Brown, Jennifer R. ^{[1
]}

Harb, Wael A. ^{[2
]}

Hill, Brian T. ^{[3
]}

Gabrilove, Janice ^{[4
]}

Sharman, Jeff P. ^{[5
]}

Schreeder, Marshall T. ^{[6
]}

Barr, Paul M. ^{[7
]}

Foran, James M. ^{[8
]}

Miller, Thomas P. ^{[9
]}

Burger, Jan A. ^{[10
]}

Kelly, Kevin R. ^{[11
]}

Mahadevan, Daruka ^{[12
]}

Ma, Shuo ^{[13
]}

Li, Yan ^{[14
]}

Pierce, Daniel W. ^{[14
]}

Barnett, Evelyn ^{[15
]}

Marine, Jeffrey ^{[15
]}

Miranda, Monika ^{[15
]}

Azaryan, Ada ^{[16
]}

Yu, Xujie ^{[16
]}

Nava-Parada, Pilar ^{[15
]}

Mei, Jay ^{[15
]}

Kipps, Thomas J. ^{[17
]}

机构：

[1] Dana Farber Canc Inst, Boston, MA USA

[2] Horizon Oncol Ctr, Lafayette, IN USA

[3] Cleveland Clin, Taussig Canc Inst, Dept Hematol & Med Oncol, Cleveland, OH 44195 USA

[4] Icahn Sch Med Mt Sinai, Tisch Canc Inst, New York, NY 10029 USA

[5] US Oncol Res, Willamette Valley Canc Inst & Res Ctr, Eugene, OR USA

[6] Clearview Canc Inst, Huntsville, AL USA

[7] Univ Rochester, Med Ctr, Hematol Oncol, Rochester, NY 14642 USA

[8] Mayo Clin, Hematol & Oncol, Jacksonville, FL USA

[9] Univ Arizona, Ctr Canc, Tucson, AZ USA

[10] Univ Texas Houston, MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA

[11] Univ Texas Hlth Sci Ctr San Antonio, CTRC Inst Drug Dev, San Antonio, TX 78229 USA

[12] Univ Tennessee, Ctr Hlth Sci, ACORN Res LLC, West Clin, Memphis, TN 38163 USA

[13] Northwestern Univ, Feinberg Sch Med, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA

[14] Celgene Corp, Dept Translat Med, San Francisco, CA USA

[15] Celgene Corp, Summit, NJ USA

[16] Celgene Corp, Berkeley Hts, NJ USA

[17] Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA 92093 USA

来源：

HAEMATOLOGICA | 2016年 / 101卷 / 07期

关键词：

CC-292; single-agent; chronic lymphocytic leukemia; small lymphocytic lymphoma; relapsed; refractory; BTK inhibitors; B-CELL RECEPTOR; TARGETING BTK; IBRUTINIB; LYMPHOMA;

D O I：

10.3324/haematol.2015.140806

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：295 / 298

页数：4

共 13 条

[1] B cell receptor signaling in chronic lymphocytic leukemia [J].

Burger, Jan A. ;

Chiorazzi, Nicholas .

TRENDS IN IMMUNOLOGY, 2013, 34 (12) :592-601

[2] Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia [J].

Byrd, J. C. ;

Brown, J. R. ;

O'Brien, S. ;

Barrientos, J. C. ;

Kay, N. E. ;

Reddy, N. M. ;

Coutre, S. ;

Tam, C. S. ;

Mulligan, S. P. ;

Jaeger, U. ;

Devereux, S. ;

Barr, P. M. ;

Furman, R. R. ;

Kipps, T. J. ;

Cymbalista, F. ;

Pocock, C. ;

Thornton, P. ;

Caligaris-Cappio, F. ;

Robak, T. ;

Delgado, J. ;

Schuster, S. J. ;

Montillo, M. ;

Schuh, A. ;

de Vos, S. ;

Gill, D. ;

Bloor, A. ;

Dearden, C. ;

Moreno, C. ;

Jones, J. J. ;

Chu, A. D. ;

Fardis, M. ;

McGreivy, J. ;

Clow, F. ;

James, D. F. ;

Hillmen, P. .

NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (03) :213-223

[3] Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia [J].

Byrd, John C. ;

Harrington, Bonnie ;

O'Brien, Susan ;

Jones, Jeffrey A. ;

Schuh, Anna ;

Devereux, Steve ;

Chaves, Jorge ;

Wierda, William G. ;

Awan, Farrukh T. ;

Brown, Jennifer R. ;

Hillmen, Peter ;

Stephens, Deborah M. ;

Ghia, Paolo ;

Barrientos, Jacqueline C. ;

Pagel, John M. ;

Woyach, Jennifer ;

Johnson, Dave ;

Huang, Jane ;

Wang, Xiaolin ;

Kaptein, Allard ;

Lannutti, Brian J. ;

Covey, Todd ;

Fardis, Maria ;

McGreivy, Jesse ;

Hamdy, Ahmed ;

Rothbaum, Wayne ;

Izumi, Raquel ;

Diacovo, Thomas G. ;

Johnson, Amy J. ;

Furman, Richard R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2016, 374 (04) :323-332

[4] Three-year follow-up of treatment-naive and previously treated patients with CLL and SLL receiving single-agent ibrutinib [J].

Byrd, John C. ;

Furman, Richard R. ;

Coutre, Steven E. ;

Burger, Jan A. ;

Blum, Kristie A. ;

Coleman, Morton ;

Wierda, William G. ;

Jones, Jeffrey A. ;

Zhao, Weiqiang ;

Heerema, Nyla A. ;

Johnson, Amy J. ;

Shaw, Yun ;

Bilotti, Elizabeth ;

Zhou, Cathy ;

James, Danelle F. ;

O'Brien, Susan .

BLOOD, 2015, 125 (16) :2497-2506

[5] Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia [J].

Byrd, John C. ;

Furman, Richard R. ;

Coutre, Steven E. ;

Flinn, Ian W. ;

Burger, Jan A. ;

Blum, Kristie A. ;

Grant, Barbara ;

Sharman, Jeff P. ;

Coleman, Morton ;

Wierda, William G. ;

Jones, Jeffrey A. ;

Zhao, Weiqiang ;

Heerema, Nyla A. ;

Johnson, Amy J. ;

Sukbuntherng, Juthamas ;

Chang, Betty Y. ;

Clow, Fong ;

Hedrick, Eric ;

Buggy, Joseph J. ;

James, Danelle F. ;

O'Brien, Susan .

NEW ENGLAND JOURNAL OF MEDICINE, 2013, 369 (01) :32-42

[6] Novel Targeted Agents and the Need to Refine Clinical End Points in Chronic Lymphocytic Leukemia [J].

Cheson, Bruce D. ;

Byrd, John C. ;

Rai, Kanti R. ;

Kay, Neil E. ;

O'Brien, Susan M. ;

Flinn, Ian W. ;

Wiestner, Adrian ;

Kipps, Thomas J. .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (23) :2820-2822

[7] Inhibition of Btk with CC-292 Provides Early Pharmacodynamic Assessment of Activity in Mice and Humans [J].

Evans, Erica K. ;

Tester, Richland ;

Aslanian, Sharon ;

Karp, Russell ;

Sheets, Michael ;

Labenski, Matthew T. ;

Witowski, Steven R. ;

Lounsbury, Heather ;

Chaturvedi, Prasoon ;

Mazdiyasni, Hormoz ;

Zhu, Zhendong ;

Nacht, Mariana ;

Freed, Martin I. ;

Petter, Russell C. ;

Dubrovskiy, Alex ;

Singh, Juswinder ;

Westlin, William F. .

JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2013, 346 (02) :219-228

[8] Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia:: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines [J].

Hallek, Michael ;

Cheson, Bruce D. ;

Catovsky, Daniel ;

Caligaris-Cappio, Federico ;

Dighiero, Guillaume ;

Doehner, Hartmut ;

Hillmen, Peter ;

Keating, Michael J. ;

Montserrat, Emili ;

Rai, Kanti R. ;

Kipps, Thomas J. .

BLOOD, 2008, 111 (12) :5446-5456

[9] Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib [J].

Jain, Preetesh ;

Keating, Michael ;

Wierda, William ;

Estrov, Zeev ;

Ferrajoli, Alessandra ;

Jain, Nitin ;

George, Binsah ;

James, Danelle ;

Kantarjian, Hagop ;

Burger, Jan ;

O'Brien, Susan .

BLOOD, 2015, 125 (13) :2062-2067

[10] Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia [J].

Maddocks, Kami J. ;

Ruppert, Amy S. ;

Lozanski, Gerard ;

Heerema, Nyla A. ;

Zhao, Weiqiang ;

Abruzzo, Lynne ;

Lozanski, Arletta ;

Davis, Melanie ;

Gordon, Amber ;

Smith, Lisa L. ;

Mantel, Rose ;

Jones, Jeffrey A. ;

Flynn, Joseph M. ;

Jaglowski, Samantha M. ;

Andritsos, Leslie A. ;

Awan, Farrukh ;

Blum, Kristie A. ;

Grever, Michael R. ;

Johnson, Amy J. ;

Byrd, John C. ;

Woyach, Jennifer A. .

JAMA ONCOLOGY, 2015, 1 (01) :80-87

← 1 2 →